<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87119">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01971021</url>
  </required_header>
  <id_info>
    <org_study_id>EPN Linkoping 2013/56-31</org_study_id>
    <nct_id>NCT01971021</nct_id>
  </id_info>
  <brief_title>Vascular Access in Cancer Patients - PICC vs PORT in a Randomized Controlled Trial.</brief_title>
  <official_title>Vascular Access in Cancer Patients - PICC vs PORT in a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Linkoeping University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ryhov County Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Linkoeping University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As of today there is very limited scientific knowledge in whicj of the two vascular access
      devices (PICC-line or venous ports) that offers the lowest complicationrates in
      cancerpatients. The study group wants to clearify this unsolved matter by comparing the two
      systems. Our primary endpoint is the presens of catheter related venous thrombosis. We are
      also looking at all catheter related complications and patient satisfaction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <primary_completion_date type="Actual">February 6, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>The occurence of catheter related venous thrombosis</measure>
    <time_frame>Upon clinical suspiscion during the one the patient i enrolled in the study</time_frame>
    <description>regular follow-ups at month 1, 3, 6 and 12.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">400</enrollment>
  <condition>Focus of Study</condition>
  <arm_group>
    <arm_group_label>PICC-line or venous port</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Randomization between two well established clinical routine vascular access devices</intervention_name>
    <arm_group_label>PICC-line or venous port</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cancer and the need for central venous access
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cancer treatment with need for central venous access

          -  Age &gt;18 yrs

          -  Suspected survival &gt; 4 weeks

          -  Need of central venous access &gt;4 weeks

        Exclusion Criteria:

          -  Ongoing uncontrolled systemic infection

          -  Prescence of significant thrombosis/stenosis in arm or central veins

          -  Unability to communicate

          -  Probable upcoming need for dialysis fistula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept of Oncology</name>
      <address>
        <city>Jönköping</city>
        <zip>551 11</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 2, 2017</lastchanged_date>
  <firstreceived_date>September 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Linkoeping University</investigator_affiliation>
    <investigator_full_name>Knut Taxbro</investigator_full_name>
    <investigator_title>MD Consultant in Anesthesia and Intensive Care</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
